Advancements in the treatment of differentiated thyroid cancer

Latoya A Stewart, Jennifer H Kuo, Latoya A Stewart, Jennifer H Kuo

Abstract

Derived from follicular epithelial cells, differentiated thyroid cancer (DTC) accounts for the majority of thyroid malignancies. The threefold increase in DTC incidence over the last three decades has been largely attributed to advancements in detection of papillary thyroid microcarcinomas. Efforts to address the issue of overtreatment have notably included the reclassification of encapsulated follicular variant papillary thyroid cancers (EFVPTC) to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). In the last 5 years, the overall management approach for this relatively indolent cancer has become less aggressive. Although surgery and radioiodine ablation remain the mainstay of DTC therapy, the role of active surveillance is being explored. Furthermore, the most recent American Thyroid Association (ATA) guidelines offer flexibility between lobectomy and total thyroidectomy for thyroid nodules between 1 cm and 4 cm in the absence of extrathyroidal extension or nodal disease. As our understanding of the natural history and molecular underpinnings of DTC evolves, so might our approach to managing low-risk patients, obviating the need for invasive intervention. Simultaneously, advances in interventional and systemic therapies have greatly expanded treatment options for high-risk surgical candidates and patients with widespread disease, and continue to be areas of active investigation. Continued research efforts are essential to improve our ability to offer effective individualized therapy to patients at all disease stages and to reduce the incidence of recurrent and progressive disease.

Keywords: DTC; differentiated thyroid cancer; management; therapy; thyroid carcinoma; treatment options.

Conflict of interest statement

Conflict of interest statement: Jennifer H. Kuo is the recipient of an early investigator grant from the American Thyroid Association and Thyroid Cancer Survivor’s Association

© The Author(s), 2021.

References

    1. SEER Cancer Stat Facts. Thyroid cancer. Bethesda, MD: National Cancer Institute, (accessed 9 October 2020).
    1. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381: 1058–1069.
    1. Thorneycroft IH. Thyroid cancer. Clin Obstet Gynecol 2002; 45: 879–883.
    1. Yip L, Sosa JA. Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment. JAMA Surg 2016; 151: 663–670.
    1. Yoo JY, Stang MT. Current guidelines for postoperative treatment and follow-up of well-differentiated thyroid cancer. Surg Oncol Clin N Am 2016; 25: 41–59.
    1. Grani G, Lamartina L, Durante C, et al.. Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol 2018; 6: 500–514.
    1. Perri F, Giordano A, Pisconti S, et al.. Thyroid cancer management: from a suspicious nodule to targeted therapy. Anticancer Drugs 2018; 29: 483–490.
    1. Lechner MG, Praw SS, Angell TE. Treatment of differentiated thyroid carcinomas. Surg Pathol Clin 2019; 12: 931–942.
    1. Carling T, Udelsman R. Thyroid cancer. Annu Rev Med 2014; 65: 125–137.
    1. Lebastchi AH, Callender GG. Thyroid cancer. Curr Probl Cancer 2014; 38: 48–74.
    1. Massimino M, Evans DB, Podda M, et al.. Thyroid cancer in adolescents and young adults. Pediatr Blood Cancer 2018; 65: e27025.
    1. Narayanan S, Colevas AD. Current standards in treatment of radioiodine refractory thyroid cancer. Curr Treat Options Oncol 2016; 17: 30.
    1. Rusinek D, Chmielik E, Krajewska J, et al.. Current advances in thyroid cancer management. Are we ready for the epidemic rise of diagnoses? Int J Mol Sci 2017; 18: 1817.
    1. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016; 12: 646–653.
    1. Kitahara CM, Gamborg M, Berrington de González A, et al.. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer Res 2014; 74: 235–242.
    1. Kitahara CM, Linet MS, Beane Freeman LE, et al.. Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control 2012; 23: 1615–1624.
    1. Lim H, Devesa SS, Sosa JA, et al.. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017; 317: 1338–1348.
    1. Raue F, Frank-Raue K. Thyroid cancer: risk-stratified management and individualized therapy. Clin Cancer Res 2016; 22: 5012–5021.
    1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140: 317–322.
    1. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes 2017; 24: 332–336.
    1. Nikiforov YE, Seethala RR, Tallini G, et al.. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016; 2: 1023–1029.
    1. Force USPST, Bibbins-Domingo K, Grossman DC, et al.. Screening for thyroid cancer: US preventive services task force recommendation statement. JAMA 2017; 317: 1882–1887.
    1. Haugen BR, Sawka AM, Alexander EK, et al.. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid 2017; 27: 481–483.
    1. Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol 2018; 14: 670–683.
    1. Haugen BR, Alexander EK, Bible KC, et al.. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1–133.
    1. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017; 27: 1341–1346.
    1. Luster M, Weber T, Verburg FA. Differentiated thyroid cancer-personalized therapies to prevent overtreatment. Nat Rev Endocrinol 2014; 10: 563–574.
    1. Ito Y, Miyauchi A, Kihara M, et al.. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014; 24: 27–34.
    1. Miyauchi A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J Surg 2016; 40: 516–522.
    1. Tuttle RM, Fagin JA, Minkowitz G, et al.. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 2017; 143: 1015–1020.
    1. Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer 2017; 123: 372–381.
    1. Haymart MR, Esfandiari NH, Stang MT, et al.. Controversies in the management of low-risk differentiated thyroid cancer. Endocr Rev 2017; 38: 351–378.
    1. McDow AD, Pitt SC. Extent of surgery for low-risk differentiated thyroid cancer. Surg Clin North Am 2019; 99: 599–610.
    1. Jillard CL, Scheri RP, Sosa JA. What is the optimal treatment of papillary thyroid cancer? Adv Surg 2015; 49: 79–93.
    1. James BC, Timsina L, Graham R, et al.. Changes in total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer during the past 15 years. Surgery 2019; 166: 41–47.
    1. Cooper DS, Doherty GM, Haugen BR, et al.. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109–142.
    1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al.. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214.
    1. Tuttle RM. Controversial issues in thyroid cancer management. J Nucl Med 2018; 59: 1187–1194.
    1. Adam MA, Thomas S, Youngwirth L, et al.. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg 2017; 265: 402–407.
    1. Hauch A, Al-Qurayshi Z, Randolph G, et al.. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014; 21: 3844–3852.
    1. Segel JM, Duke WS, White JR, et al.. Outpatient thyroid surgery: safety of an optimized protocol in more than 1,000 patients. Surgery 2016; 159: 518–523.
    1. Terris DJ, Snyder S, Carneiro-Pla D, et al.. American thyroid association statement on outpatient thyroidectomy. Thyroid 2013; 23: 1193–1202.
    1. Berdelou A, Lamartina L, Klain M, et al.. Treatment of refractory thyroid cancer. Endocr Relat Cancer 2018; 25: R209–R223.
    1. Doubleday A, Sippel RS. Surgical options for thyroid cancer and post-surgical management. Expert Rev Endocrinol Metab 2018; 13: 137–148.
    1. Lee DY, Seok J, Jeong WJ, et al.. Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res 2015; 193: 273–278.
    1. Schlumberger M, Borget I, Nascimento C, et al.. Treatment and follow-up of low-risk patients with thyroid cancer. Nat Rev Endocrinol 2011; 7: 625–628.
    1. Haddad RI, Nasr C, Bischoff L, et al.. NCCN guidelines insights: thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw 2018; 16: 1429–1440.
    1. Nikiforova MN, Mercurio S, Wald AI, et al.. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 2018; 124: 1682–1690.
    1. Steward DL, Carty SE, Sippel RS, et al.. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol 2019; 5: 204–212.
    1. Patel KN, Angell TE, Babiarz J, et al.. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg 2018; 153: 817–824.
    1. Krane JF, Cibas ES, Endo M, et al.. The afirma Xpression atlas for thyroid nodules and thyroid cancer metastases: insights to inform clinical decision-making from a fine-needle aspiration sample. Cancer Cytopathol 2020; 128: 452–459.
    1. Lupo MA, Walts AE, Sistrunk JW, et al.. Multiplatform molecular test performance in indeterminate thyroid nodules. Diagn Cytopathol 2020; 48: 1254–1264.
    1. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676–690.
    1. Song YS, Yoo SK, Kim HH, et al.. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr Relat Cancer 2019; 26: 629–641.
    1. Jin A, Xu J, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore) 2018; 97: e11548.
    1. Insilla AC, Proietti A, Borrelli N, et al.. TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases. Oncol Lett 2018; 15: 2763–2770.
    1. Trybek T, Walczyk A, Gasior-Perczak D, et al.. Impact of BRAF V600E and TERT promoter mutations on response to therapy in papillary thyroid cancer. Endocrinology 2019; 160: 2328–2338.
    1. Shaha MA, Wang LY, Migliacci JC, et al.. Previous external beam radiation treatment exposure does not confer worse outcome for patients with differentiated thyroid cancer. Thyroid 2017; 27: 412–417.
    1. Rothenberg SM, McFadden DG, Palmer EL, et al.. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 2015; 21: 1028–1035.
    1. Viola D, Valerio L, Molinaro E, et al.. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 2016; 23: R185–R205.
    1. Reiners C, Luster M. Radiotherapy: radioiodine in thyroid cancer-how to minimize side effects. Nat Rev Clin Oncol 2012; 9: 432–434.
    1. Schlumberger M, Leboulleux S, Catargi B, et al.. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol 2018; 6: 618–626.
    1. Kreissl MC, Janssen MJR, Nagarajah J. Current treatment strategies in metastasized differentiated thyroid cancer. J Nucl Med 2019; 60: 9–15.
    1. Grewal RK, Ho A, Schoder H. Novel approaches to thyroid cancer treatment and response assessment. Semin Nucl Med 2016; 46: 109–118.
    1. Nixon IJ, Simo R, Newbold K, et al.. Management of invasive differentiated thyroid cancer. Thyroid 2016; 26: 1156–1166.
    1. Jin Y, Van Nostrand D, Cheng L, et al.. Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol 2018; 125: 111–120.
    1. Vaisman F, Tuttle RM. Clinical assessment and risk stratification in differentiated thyroid cancer. Endocrinol Metab Clin North Am 2019; 48: 99–108.
    1. Ibrahim EY, Busaidy NL. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer. Curr Opin Oncol 2017; 29: 151–158.
    1. Schmidt A, Iglesias L, Klain M, et al.. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab 2017; 61: 81–89.
    1. Hirsch D, Gorshtein A, Robenshtok E, et al.. Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease. J Clin Endocrinol Metab 2018; 103: 469–476.
    1. Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43: 401–421.
    1. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016; 388: 2783–2795.
    1. Hartl DM, Hadoux J, Guerlain J, et al.. Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer. Best Pract Res Clin Endocrinol Metab 2019; 33: 101281.
    1. Tarasova VD, Tuttle RM. A risk-adapted approach to follow-up in differentiated thyroid cancer. Rambam Maimonides Med J 2016; 7: e0004.
    1. Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab 2019; 104: 4087–4100.
    1. Ozkan E, Soydal C, Nak D, et al.. Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer. Nucl Med Commun 2017; 38: 1055–1059.
    1. Momesso DP, Vaisman F, Yang SP, et al.. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab 2016; 101: 2692–2700.
    1. Cho JW, Lee YM, Lee YH, et al.. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients. Clin Endocrinol (Oxf) 2018; 89: 100–109.
    1. Ritter A, Mizrachi A, Bachar G, et al.. Detecting recurrence following lobectomy for thyroid cancer: role of thyroglobulin and thyroglobulin antibodies. J Clin Endocrinol Metab 2020; 105: dgaa152.
    1. Kiess AP, Agrawal N, Brierley JD, et al.. External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American head and neck society. Head Neck 2016; 38: 493–498.
    1. Fussey JM, Crunkhorn R, Tedla M, et al.. External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck 2016; 38(Suppl. 1): E2297–E2305.
    1. Bonichon F, Buy X, Godbert Y, et al.. Local treatment of metastases from differentiated thyroid cancer. Ann Endocrinol (Paris) 2015; 76(Suppl. 1): 1S40–1S46.
    1. Tam S, Amit M, Boonsripitayanon M, et al.. Adjuvant external beam radiotherapy in locally advanced differentiated thyroid cancer. JAMA Otolaryngol Head Neck Surg 2017; 143: 1244–1251.
    1. Makita K, Hamamoto Y, Tsuruoka S, et al.. Treatment intensity and control rates in combining external-beam radiotherapy and radioactive iodine therapy for metastatic or recurrent differentiated thyroid cancer. Int J Clin Oncol 2020; 25: 691–697.
    1. Giuliani M, Brierley J. Indications for the use of external beam radiation in thyroid cancer. Curr Opin Oncol 2014; 26: 45–50.
    1. Yi PQ, Nie FF, Fan YB, et al.. Intraoperative radiotherapy for the treatment of thyroid cancer: a pilot study. Oncotarget 2017; 8: 29355–29360.
    1. Ji L, Wu Q, Gu J, et al.. Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients. Cancer Imaging 2019; 19: 16.
    1. Ding M, Tang X, Cui D, et al.. Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma. Clin Radiol 2019; 74: 712–717.
    1. Brito JP, Hay ID. Management of papillary thyroid microcarcinoma. Endocrinol Metab Clin North Am 2019; 48: 199–213.
    1. Hahn SY, Shin JH, Na DG, et al.. Ethanol ablation of the thyroid nodules: 2018 consensus statement by the Korean society of thyroid radiology. Korean J Radiol 2019; 20: 609–620.
    1. U.S. Department of Health and Human Services. Drugs @ FDA: FDA-approved drugs. Silver Spring, MD: US Food and Drug Administration, (accessed 30 December 2020).
    1. Brose MS, Nutting CM, Jarzab B, et al.. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319–328.
    1. Schlumberger M, Tahara M, Wirth LJ, et al.. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621–630.
    1. Kiyota N, Robinson B, Shah M, et al.. Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial. Thyroid 2017; 27: 1135–1141.
    1. Brose MS, Worden FP, Newbold KL, et al.. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol 2017; 35: 2692–2699.
    1. Wirth LJ, Sherman E, Robinson B, et al.. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020; 383: 825–835.
    1. Naoum GE, Morkos M, Kim B, et al.. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer 2018; 17: 51.
    1. Bible KC, Menefee ME, Lin CJ, et al.. An international phase 2 study of pazopanib in progressive and metastatic thyroglobulin antibody negative radioactive iodine refractory differentiated thyroid cancer. Thyroid 2020; 30: 1254–1262.
    1. Worden F, Fassnacht M, Shi Y, et al.. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer 2015; 22: 877–887.
    1. Grevel J, Jentsch G, Austin R, et al.. Exposure-response modeling and simulation of progression-free survival and adverse events of sorafenib treatment in patients with advanced thyroid cancer. Clin Transl Sci 2019; 12: 459–469.
    1. Wirth LJ, Tahara M, Robinson B, et al.. Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 2018; 124: 2365–2372.
    1. Ho AL, Grewal RK, Leboeuf R, et al.. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368: 623–632.
    1. Dunn LA, Sherman EJ, Baxi SS, et al.. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J Clin Endocrinol Metab 2019; 104: 1417–1428.
    1. Kebebew E, Lindsay S, Clark OH, et al.. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 2009; 19: 953–956.
    1. Kebebew E, Peng M, Reiff E, et al.. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006; 140: 960–966; discussion 6–7.
    1. Rosenbaum-Krumme SJ, Freudenberg LS, Jentzen W, et al.. Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by 124I PET/CT imaging. Clin Nucl Med 2012; 37: e47–e52.
    1. Short SC, Suovuori A, Cook G, et al.. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 2004; 16: 569–574.
    1. Groener JB, Gelen D, Mogler C, et al.. BRAF V600E and retinoic acid in radioiodine-refractory papillary thyroid cancer. Horm Metab Res 2019; 51: 69–75.
    1. Sherman EJ, Su YB, Lyall A, et al.. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid 2013; 23: 593–599.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera